Revolution Medicines (RVMD) Non Operating Income (2019 - 2026)

Revolution Medicines' Non Operating Income history runs 8 years deep, the most recent figure standing at -$8.6 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 85840.0% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at $59.4 million (down 55.64% YoY), while the FY2025 annual figure was $51.1 million, down 42.41% from the prior year.
• Non Operating Income was -$8.6 million for Q1 2026 at Revolution Medicines, down from $51.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $91.2 million in Q4 2024 to a low of -$8.6 million in Q1 2026.
• Historically, Non Operating Income has averaged $17.2 million across 5 years, with a median of $8.8 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Non Operating Income surged 2237.42% in 2023, then tumbled 85840.0% in 2026.
• A 5-year view of Non Operating Income shows it stood at $5.1 million in 2022, then surged by 831.53% to $47.3 million in 2023, then surged by 92.81% to $91.2 million in 2024, then slumped by 43.95% to $51.1 million in 2025, then plunged by 116.81% to -$8.6 million in 2026.
• The last three Non Operating Income figures came in at -$8.6 million (Q1 2026), $51.1 million (Q4 2025), and $16.9 million (Q2 2025), per Business Quant data.